Cerebrolysin is a peptide preparation produced by the enzymatic hydrolysis of porcine brain protein. It is a mixture rather than a single defined molecule — low-molecular-weight peptides and free amino acids — studied for reported neurotrophic and neuroprotective activity. In the research literature it appears chiefly in three contexts: acute ischaemic stroke, traumatic brain injury and Alzheimer's disease.

This article summarises the published research only. Cerebrolysin holds marketing authorisations in several non-UK jurisdictions but not in the UK; it is not licensed by the MHRA, and it is studied here as a research compound. Nothing below is consumption advice and nothing is a dosing instruction — where trial methodology is described, it is described as methodology, not as use.

Mechanism

The preparation is reported to mimic endogenous neurotrophic factors, including BDNF, NGF and GDNF, through a multi-modal action that includes neurotrophic signalling, reduced excitotoxicity and modulation of apoptotic pathways. That mechanism is inferred largely from preclinical work. The preparation's heterogeneity makes a single receptor-level mechanism difficult to isolate.

Acute ischaemic stroke

The largest confirmatory trial is CASTA (Heiss 2012), which randomised 1,070 patients with acute ischaemic stroke in Asia. Its confirmatory endpoint was neutral. A post hoc subgroup analysis in patients with an NIHSS score above 12 reported 90-day mortality of 20.2% with placebo against 10.5% with Cerebrolysin (HR 1.9661; lower confidence bound 1.0013) — a hypothesis-generating signal, not a confirmatory result.

CARS (Muresanu 2016) randomised 208 patients and reported a positive result on its primary endpoint, the Action Research Arm Test at day 90, with a Mann-Whitney estimator of 0.71 (0.63-0.79), alongside a standardised rehabilitation programme delivered in the trial protocol.

Against this, the Cochrane review of Cerebrolysin for acute ischaemic stroke (Ziganshina 2020) pooled seven randomised trials and 1,601 participants and found no demonstrated clinical benefit on clinically relevant outcomes such as death or dependence. An earlier update reported moderate-quality evidence of an increase in non-fatal serious adverse events.

Traumatic brain injury

The CAPTAIN I and II trials, together with a prospective meta-analysis (Vester 2021), report improved Glasgow outcome measures in traumatic brain injury. That programme is manufacturer-linked, and the relationship is stated here rather than left implicit. Other meta-analyses in this indication, such as Ghaffarpasand 2018, report improvements in Glasgow Coma Scale and Glasgow Outcome Scale scores, with no demonstrated effect on mortality.

Alzheimer's disease

A meta-analysis of randomised controlled trials (Gauthier 2015) reported cognitive benefit at four weeks but not at six months. The finding is time-limited and has not translated into a licensed indication.

UK legal status

Cerebrolysin is not authorised by the MHRA and holds no UK marketing authorisation. Unlicensed supply and importation are governed by the Medicines Act 1968 and the Human Medicines Regulations 2012, including the exemptions that apply to research use; supplying an unlicensed medicine is a regulated activity. This site lists Cerebrolysin with evidence grade Moderate and UK status POM.

Evidence grade

Moderate. The trial record is unusually large for a research peptide, but it is divided: a positive rehabilitation trial and a neutral confirmatory trial sit beside a Cochrane review that finds no demonstrated clinical benefit on clinically relevant outcomes. On that basis the evidence does not reach the Strong grade.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.